The preclinical toxicological evaluation of sumatriptan.
1 Sumatriptan is a potent and selective 5-HT1 receptor agonist marketed for the treatment of migraine by both oral and subcutaneous routes. An extensive toxicological programme employing high doses of sumatriptan was carried out in a range of animal species. The studies evaluated both the local and systemic tolerance to single and repeated dosing, effects on all stages of reproduction, as well as the genotoxic and oncogenic potential of sumatriptan. 2 The administration of relatively high single and repeated doses of sumatriptan was well tolerated by both rodents and dogs by the oral, subcutaneous and intravenous routes. Behavioural effects, suggestive of involvement of the central nervous system, were the most obvious result of such doses and were generally more pronounced in dogs than rodents. The reason for this may be related to the higher plasma concentrations of the drug achievable in dogs. Additional observations restricted to dogs, were transient, and included tachycardia, facial oedema and breaks in the continuity of secretion films on the corneal surface. A tendency for an increase in weight gain was seen for rats, while a slight decrease was usually seen for dogs. The only pathological changes related to treatment with high concentrations of sumatriptan consisted of local reactions at the site of subcutaneous administration. 3 Sumatriptan is an indole; the structures of this chemical class show varying propensities for nitrosation. However, appropriate testing with sumatriptan failed to identify any mutagenic nitroso compounds. 4 Sumatriptan was neither genotoxic nor oncogenic. 5 Reproductive studies demonstrated that sumatriptan was not teratogenic and had no effect on peri- and postnatal development. Some embryotoxicity was observed, but only at maternally toxic doses. A slight decrease in the success of insemination was also noted at high oral doses in rats. 6 Results of the toxicological programme performed in support of migraine therapy with sumatriptan provide good assurance of safety for subcutaneous and oral use.
Owen
K
K
Glaxo Research and Development Ltd, Park Road, Ware, Hertfordshire, UK.
Hartley
K
K
Tucker
M L
ML
Parkinson
M M
MM
Tweats
D J
DJ
Jackson
M R
MR
D000284:Administration, Oral; D000704:Analysis of Variance; D000818:Animals; D015415:Biomarkers / Q000097:blood; D001773:Blood Cells / Q000187:drug effects; D002273:Carcinogens / Q000008:administration & dosage / Q000633:toxicity*; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005314:Embryonic and Fetal Development / Q000187:drug effects; D005260:Female; D005298:Fertility / Q000187:drug effects; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D008297:Male; D051379:Mice; D009152:Mutagenicity Tests; D009153:Mutagens / Q000008:administration & dosage / Q000633:toxicity*; D011817:Rabbits; D051381:Rats; D012098:Reproduction / Q000187:drug effects*; D018570:Risk Assessment; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage / Q000633:toxicity*; D013045:Species Specificity; D018170:Sumatriptan / Q000008:administration & dosage / Q000633:toxicity*
D015415:Biomarkers; D002273:Carcinogens; D009153:Mutagens; D017366:Serotonin Receptor Agonists; D018170:Sumatriptan